IDWeek 2018
AWG Member Company Participation at IDWeek 2018
Sixteen AWG member companies presented data from their clinical and research programs at IDWeek 2018 held October 3-7 in San Francisco, CA. Representatives from AWG member companies presented a total of 40 poster presentations, four oral abstract presentations and four features within the symposium entitled “Exploring the Antibiotic Pipeline 2018.”
IDWeek is an annual scientific meeting that brings together infectious disease professionals to present and discuss the latest approaches in prevention, diagnosis, treatment, and epidemiology of infectious diseases.
Thursday, October 4
Oral Abstract Session: Late Breaker Oral Abstracts: HIV and Antibiotic Trials
Time: 10:30am – 11:45am PT
Location: S 151-153
Nabriva Therapeutics:
11:20am – 11:30am PT
- Oral Lefamulin Is Safe and Effective in the Treatment of Adults with Community-Acquired Bacterial Pneumonia (CABP): Results of Lefamulin Evaluation Against Pneumonia (LEAP 2) Study
Poster Abstract Session: Bone and Joint Infections
Time: 12:30pm – 1:45pm PT
Location: S Poster Hall
Melinta Therapeutics:
- #290 – Safety and effectiveness of oral sodium fusidate (fusidic acid) as chronic antibiotic suppressive therapy in patients with staphylococcal bone or joint infections.
Symposium: Exploring the Antibiotic Pipeline 2018
Time: 2:00pm – 3:15pm PT
Location: N Hall D
https://idsa.confex.com/idsa/2018/webprogram/Session10235.html
- ContraFect – 2:15pm PT
- Spero Therapeutics – 2:30pm PT
- SCYNEXIS – 2:45pm PT
- Entasis Therapeutics – 3:00pm PT
Friday, October 5
Poster Abstract Session: Novel Agents
Time: 12:30pm – 1:45pm PT
Location: S Poster Hall
Contrafect:
- #1342 – Comparison of Lysin CF-301 (Exebacase) Activity Against S. aureus Isolates from Bacteremic Patients Enrolled in a Phase 2 Study (CF-301-102) to Contemporary Surveillance Isolates
Iterum Therapeutics:
- #1363 – Sulopenem Activity against Enterobacteriaceae Isolates from Patients with Urinary Tract Infection or Intra-Abdominal Infection
Motif Bio:
- #1338 – A Pooled Analysis of Patients with Wound Infections in the Phase 3 REVIVE Trials: Randomized, Double-blind Studies to Evaluate the Safety and Efficacy of Iclaprim Versus Vancomycin for treatment of Acute Bacterial Skin and Skin Structure Infections
Nabriva Therapeutics:
- #1365 – In Vitro Activity of Lefamulin (LEF) Against Bacterial Pathogens Causing Community-Acquired Bacterial Pneumonia (CABP): SENTRY Surveillance 2016 Results from Asia-Pacific (APAC) and Latin America (LA)
- #1367 – Clinical Cure in Secondary Efficacy Populations in Patients with Complicated Urinary Tract Infection Treated with ZTI-01 (fosfomycin for injection): Findings from the ZEUS Trial
Paratek Pharmaceuticals:
- #1347 – Omadacycline for Acute Bacterial Skin and Skin Structure Infections: Integrated Analysis of Randomized Clinical Trials
- #1356 – Improvement in Quality of Life for Adults with Acute Bacterial Skin and Skin Structure Infections Following Treatment with Omadacycline or Linezolid
- #1364 – Efficacy of Omadacycline against Molecularly Characterized Gram-Positive and Gram-Negative Pathogens Causing Infections in the Phase 3 CABP and ABSSSI Clinical Trials
- #1374 – Integrated Safety Summary of Omadacycline: A Novel Aminomethylcycline Antibiotic
- #1377 – Omadacycline In Vitro Activity against a Molecularly Characterized Collection of Clinical Isolates with Known Tetracycline Resistance Mechanisms
Summit Therapeutics:
- #1344 – Ridinilazole (RDZ) for Clostridium difficile Infection (CDI): Impact of Diagnostic Method on Outcomes from a Phase 2 Clinical Trial
- #1361 – Pharmacokinetics and Safety of Ridinilazole (RDZ), a Potential New Therapy for Clostridium difficile Infection (CDI): from Animal Models to Patients
- #1369 – Combined Analysis of the In Vitro Activity of Ridinilazole (RDZ) Against More Than 500 Clostridium difficile (CD) Clinical Isolates and Impact of RDZ on Cell Morphology
Amplyx Pharmaceuticals
- #1340 – Population Pharmacokinetic (PK) Analysis of APX001 Using Phase 1 Data
Viamet:
- #1346 – The Tetrazole VT-1598 is Efficacious in a Murine Model of Invasive Aspergillosis with a PK/PD Expected of a Mold-Active CYP51 Inhibitor
Poster Abstract Session: PK/PD Studies
Time: 12:30pm – 1:45pm PT
Location: S Poster Hall
Cidara Therapeutics:
- #1390 – Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Rezafungin (RZF) Dose Selection in Treatment of Candida
Iterum Therapeutics:
- #1393 – A Phase 1, Randomized, Open-Label, Crossover Study in Healthy Subjects under Fasting Conditions of Orally Administered Sulopenem Etzadroxil Alone or with Probenecid to Determine the Pharmacokinetics of Sulopenem
- #1353 – In Vitro Activity of Lefamulin (LEF) against Bacterial Pathogens Commonly Causing Community-Acquired Bacterial Pneumonia (CABP): 2016 SENTRY Data from the United States
Melinta Therapeutics:
- #1387 – Phase I study to evaluate the safety and pharmacokinetics (PK) of single and multiple ascending doses (SAD/MAD) of intravenous (IV) minocycline in healthy adult subjects
Arsanis
- #1388 – Dose Discrimination for ASN100: Bridging from Rabbit Survival Data to Predicted Activity in Humans Using a Minimal Physiologically-Based Pharmacokinetic (mPBPK) Model
- #1408 – Population Pharmacokinetic (PK) Model to Describe Epithelial Lining Fluid (ELF) Penetration of ASN-1 and ASN-2 after ASN100 Administration to Healthy Subjects
Poster Abstract Session: Urinary Tract Infection
Time: 12:30pm – 1:45pm PT
Location: S Poster Hall
Iterum Therapeutics:
- #1527 – The Prevalence of Enterobacteriaceae (ENT) Resistant to all Major Classes of Oral Antibiotics from Outpatient Urine Cultures in the United States and Effect on Clinical Outcomes
Spero Therapeutics
- #1504 – Patient demographics and comorbidity profiles associated with hospitalized patients admitted with resistant vs. susceptible urinary tract infections (UTI): A multicenter analysis
Poster Abstract Session: Healthcare Epidemiology: MDR-Gram Negative Infections
Time: 12:30pm – 1:45pm PT
Location: S Poster Hall
Melinta Therapeutics:
- #1181 – Use of the Combination Antibiogram in the Era of MDR Gram Negative Pathogens
Poster Abstract Session: Respiratory Infections: CAP
Time: 12:30pm – 1:45pm PT
Location: S Poster Hall
Paratek Pharmaceuticals:
- #1462 – Hospital Admission Patterns in Adult Patients with Community-acquired Bacterial Pneumonia who Received Ceftriaxone and a Macrolide by Pneumonia Severity Index Score
Poster Abstract Session: Fungi and Parasites in Immunocompromised Patients
Time: 12:30pm – 1:45pm PT
Location: S Poster Hall
T2 Biosystems:
- #1134 – Novel T2Candida Panel Assay Compared to Blood Cultures for Detection of Candidemia in Transplant and Non-Transplant Patients.
Saturday, October 6
Oral Abstract Session: Clinical Trials that May Change Your Practice
Time: 8:45am – 10:00am PT
Location: Room S 158
Cidara Therapeutics:
9:30am – 9:45am PT
- #1718 – Rezafungin Clinical Safety and Efficacy in Patients with Candidemia and/or Invasive Candidiasis in the Randomized, Double-blind, Multicenter, Phase 2 STRIVE Study
Melinta Therapeutics:
9:45am – 10:00am PT
- #1719 – Pharmacokinetics (PK) of Oritavancin in Children: The ORKIDS Trial
Oral Abstract Session: Translating Microbiome Science into Practice
Time: 10:30am – 11:45am PT
Location: W 2002
Summit Therapeutics:
- #1774 – Ridinilazole (RDZ) for Clostridium difficile infection (CDI): Correlation of In Vitro Spectrum of Activity with Human Gut Microbiome Profiles from a Phase 2 Clinical Trial
Poster Abstract Session: Treatment of AMR Infections
Time: 12:30pm – 1:45pm PT
Location: S Poster Hall
Cidara Therapeutics:
- #2400 – Activity of a Long-Acting Echinocandin, Rezafungin, Tested against Invasive Fungal Isolates Collected Worldwide
- #2389 – Effect of Rezafungin on QT Interval in Healthy Subjects
Nabriva Therapeutics:
- #2386 – Efficacy of Lefamulin (LEF) Versus (vs) Moxifloxacin (MOX) Against Common Pathogens in Adults with Community-Acquired Bacterial Pneumonia (CABP): Results from the Phase 3 Lefamulin Evaluation Against Pneumonia (LEAP 1) Study
Summit Therapeutics:
- #2387 – Selecting Clostridium difficile Infection (CDI) Outcome Measures Relevant to Public Health Concerns: Experience From a Ridinilazole (RDZ) Phase 2 Trial
Poster Abstract Session: Skin and Skin Structure Infection
Time: 12:30pm – 1:45pm PT
Location: S Poster Hall
Melinta Therapeutics
- #2373 – Evaluation of Delafloxacin Activity and Treatment Outcome for Phase 3 Acute Bacterial Skin and Skin Structure Infection Clinical Trial Anaerobic Isolates
- #2377 – Outcomes in patients with history of cardiac or vascular disease (CV) during treatment of acute bacterial skin and skin structure infection (ABSSSI) with delafloxacin (DLX) vs vancomycin/aztreonam (VAN/AZ)
- Poster #2378 – Resolution of Signs and Symptoms (S&S) of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) with Delafloxacin (DLX) IV/oral therapy
Theravance Biopharma
- #2364 – Evaluation of Renal Function Changes in Patients with Prolonged Telavancin Therapy (> 21 days): Results from the Telavancin Observational Use Registry (TOUR™)
- #2369 – Clinical Experience with Telavancin for Treatment of Patients with Monomicrobial S. aureus Infections (Vancomycin MIC ≥ 1 µg/mL) from TOUR™
Poster Abstract Session: Clinical Practice Issues: HIV, Sepsis, QI, Diagnosis
Time: 12:30pm – 1:45pm PT
Location: S Poster Hall
Melinta Therapeutics
- #1928 – Comparisons of 30-Day Admission and 30-Day Total Healthcare Costs Between Patients Who Were Treated with Oritavancin (ORI) or Vancomycin (VAN) for a Skin Infection in the Outpatient Setting
Poster Abstract Session: Diagnostics: Bacteria and MycobacteriaTime: 12:30pm – 1:45pm PTLocation: S Poster HallT2 Biosystems:
- #2006 – Implementation of the T2 Biosystems T2Bacteria Panel in a Level-One Trauma Center, Safety Net Hospital
Poster Abstract Session: Diagnostics: MycologyTime: 12:30pm – 1:45pm PTLocation: S Poster HallT2 Biosystems:
- #2041 – Impact of T2 Candida Panel on Species Specific Anti-fungal De-escalation
- #2043 – T2-Candida (T2MR) versus Beta-D-Glucan (BDG) for Preemptive Antifungal Stewardship in the Intensive Care Unit (ICU)